SGP Form 4 reports acquisition/exercise transactions

Khan Bilal Arshad reported acquisition or exercise transactions in a Form 4 filing for SGP.

Rhea-AI Filing Summary

Khan Bilal Arshad reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 13,700 shares. Following the reported transactions, holdings were 13,700 shares.

Insider Trade Summary

Grant/Award: 13,700 shares

Grant/Award 1 txn

Insider Khan Bilal Arshad

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	13,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 13,700 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SpyGlass Pharma (SGP) report for Khan Bilal Arshad?

SpyGlass Pharma reported that director Khan Bilal Arshad received a grant of 13,700 stock options. These options give him the right to buy common shares at a fixed $16 exercise price, reflecting routine equity compensation for board service.

How many SpyGlass Pharma (SGP) stock options were granted in this Form 4?

The Form 4 shows a grant of 13,700 stock options to director Khan Bilal Arshad. Each option represents the right to purchase one share of SpyGlass Pharma common stock, creating potential future ownership if the options eventually vest and are exercised.

What is the exercise price and expiry for the SpyGlass Pharma (SGP) options?

The options carry an exercise price of $16 per share and expire on February 5, 2036. This means Arshad can choose to buy shares at $16 any time after vesting and before the expiration date, subject to plan and company rules.

What are the vesting terms of the SpyGlass Pharma (SGP) director stock options?

All 13,700 options vest 100% in a single installment if Arshad continues as an Outside Director. Vesting occurs on the earlier of one year after the February 5, 2026 grant date or immediately before the next annual stockholder meeting.

Is the SpyGlass Pharma (SGP) director option grant an open-market purchase?

No, this transaction is a grant of stock options with a $16 exercise price, not an open-market share purchase. The Form 4 code “A” identifies it as a grant or award, and the transaction price of the derivative security is reported as $0.

How many SpyGlass Pharma (SGP) derivative securities does the director own after this grant?

After the reported transaction, Khan Bilal Arshad beneficially owns 13,700 derivative securities in the form of stock options. All of these options are held as direct ownership, according to the ownership coding disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:50 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Bilal Arshad

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		13,700		(1)	02/05/2036	Common Stock	13,700	$0	13,700	D

Explanation of Responses:

1. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean February 5, 2026.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.